US PHARMACEUTICAL giant Valeant has appointed investment bankers to sell iNova Pharmaceuticals, which Valeant bought for around $700m in 2011.
According to the Financial Review, Goldman Sachs is looking after the sale of the Sydney-based company which manufactures and markets a range of brands including Nyal, Difflam and Bausch & Lomb.
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Sep 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Sep 16